The thymidine kinase/ganciclovir-mediated "suicide" effect is variable in different tumor cells

Area of Science:

• Molecular Biology
• Cancer Therapy
• Gene Therapy

Background:

• The herpes simplex virus thymidine kinase (HSV-TK) gene converts ganciclovir (GCV) into a toxic product, enabling selective elimination of TK-expressing cells.
• HSV-TK is utilized in clinical gene therapy trials as both a therapeutic gene and a safety marker.

Purpose of the Study:

• To investigate the susceptibility of various tumor cell lines to the HSV-TK/GCV-mediated "suicide" effect.
• To determine if in vitro sensitivity correlates with in vivo tumor eradication efficacy.

Main Methods:

• Tumor cell lines (TSA, J558L, EB, ESB) and control NIH-3T3 cells were infected with a retrovirus encoding a hygromycin/TK fusion gene.
• Cells were exposed to varying concentrations and durations of ganciclovir (GCV) to assess in vitro sensitivity.
• In vivo studies evaluated the eradication of TK-expressing tumors following systemic GCV administration.

Main Results:

• All tested cell lines demonstrated sensitivity to GCV in vitro, but the required concentration and time for complete elimination varied significantly.
• TSA-TK cells were eliminated within 10 days using 1 microg/ml GCV, while ESB-TK cells required 22 days with 10 microg/ml GCV.
• In vivo, TSA-TK tumors were effectively eradicated by systemic GCV, whereas ESB-TK tumors were resistant, correlating with in vitro findings. Differences in sensitivity were not attributed to TK expression levels.

Conclusions:

• Tumor cells exhibit significant variability in their susceptibility to the HSV-TK/GCV suicide effect.
• In vitro susceptibility testing is a reliable predictor of in vivo therapeutic efficacy for HSV-TK/GCV gene therapy.